Abstract
MRI is the main paraclinical tool used both to diagnose multiple sclerosis (MS) and to evaluate the efficacy of experimental treatments in phase II and III clinical trials. In the latter context, a major issue is represented by the weak correlations found between clinical and MRI aspects in the case of established MS, which are particularly evident when individual patients are considered. As a consequence, the definition of response to MS treatment, when based upon MRI aspects, remains a challenging task. Although the use of MRI-derived quantities to define treatment options and strategies at an individual patient level is supported by recent evidence, only the integration of clinical and MRI data can be considered a reliable approach for the work-up of patients undergoing disease-modifying treatments.
| Original language | English |
|---|---|
| Journal | Neurological Sciences |
| Volume | 29 |
| Issue number | SUPPL. 2 |
| DOIs | |
| Publication status | Published - Sep 2008 |
Fingerprint
Keywords
- MRI
- Multiple sclerosis
- Treatment response
ASJC Scopus subject areas
- Dermatology
- Clinical Neurology
- Psychiatry and Mental health
Cite this
The definition of non-responder to multiple sclerosis treatment : Neuroimaging markers. / Rovaris, Marco.
In: Neurological Sciences, Vol. 29, No. SUPPL. 2, 09.2008.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The definition of non-responder to multiple sclerosis treatment
T2 - Neuroimaging markers
AU - Rovaris, Marco
PY - 2008/9
Y1 - 2008/9
N2 - MRI is the main paraclinical tool used both to diagnose multiple sclerosis (MS) and to evaluate the efficacy of experimental treatments in phase II and III clinical trials. In the latter context, a major issue is represented by the weak correlations found between clinical and MRI aspects in the case of established MS, which are particularly evident when individual patients are considered. As a consequence, the definition of response to MS treatment, when based upon MRI aspects, remains a challenging task. Although the use of MRI-derived quantities to define treatment options and strategies at an individual patient level is supported by recent evidence, only the integration of clinical and MRI data can be considered a reliable approach for the work-up of patients undergoing disease-modifying treatments.
AB - MRI is the main paraclinical tool used both to diagnose multiple sclerosis (MS) and to evaluate the efficacy of experimental treatments in phase II and III clinical trials. In the latter context, a major issue is represented by the weak correlations found between clinical and MRI aspects in the case of established MS, which are particularly evident when individual patients are considered. As a consequence, the definition of response to MS treatment, when based upon MRI aspects, remains a challenging task. Although the use of MRI-derived quantities to define treatment options and strategies at an individual patient level is supported by recent evidence, only the integration of clinical and MRI data can be considered a reliable approach for the work-up of patients undergoing disease-modifying treatments.
KW - MRI
KW - Multiple sclerosis
KW - Treatment response
UR - http://www.scopus.com/inward/record.url?scp=53649103143&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=53649103143&partnerID=8YFLogxK
U2 - 10.1007/s10072-008-0943-0
DO - 10.1007/s10072-008-0943-0
M3 - Article
VL - 29
JO - Neurological Sciences
JF - Neurological Sciences
SN - 1590-1874
IS - SUPPL. 2
ER -